The Glycostat systems are designed to assist in maintaining normal levels of glucose in hospitalized patients thereby preventing both hypoglycemic and hyperglycemic events.
Tight Glycemic Control in the critically ill patient is understood by physicians to promote better outcomes.
Studies show that many non-diabetic hospital patients suffer episodes of hyperglycemia. According to reference 1 , as of 1998, as many as 1.5 million hospitalized patients had significant hyperglycemia without a history of diabetes.
Ref 2 which appeared as a November 2001 article in the New England Journal of Medicine summarized a study of over 1,500 hospitalized patients, of which only 13% were diabetic, which concluded that intensive insulin therapy to maintain blood glucose levels within a target range reduced mortality and morbidity among critically ill patients in the surgical intensive care unit and improved patient outcomes This large, randomized, controlled study showed that intensive glycemic control reduced the mortality rate by 34%, the frequency of acute renal failure by 41%, bloodstream infections by 46%, and frequency of critical illness polyneuropathy by 44%.
Many additional studies, ref. 3 – 7 have confirmed the benefit of TGC and the benefit to the patient:
Kontakt os
About
Flowsion is a medical device company focused on the design, development and commercialization of a product platform specifically for the in-hospital automated glucose control and continuous glucose monitoring market.
